Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid Tumors

Trial Profile

Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs ISA 101 (Primary) ; Nivolumab
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 29 Dec 2015 Planned primary completion date changed from 1 Feb 2019 to 1 Dec 2018, as reported by ClinicalTrials.gov.
    • 07 Dec 2015 Status changed from not yet recruiting to recruiting, as reported in an ISA Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top